In January 2025 the FTC obtained orders permanently banning two chiropractic-world founders from marketing regenerative medicine and requiring payment of more than $5.1 million. The marketing, not the medicine, is what was charged.
Key Takeaways
- In January 2025, federal court orders permanently banned the Stem Cell Institute of America co-founders – one a chiropractor, one a former chiropractor – from marketing regenerative medicine treatments and required payment of $5,155,146 in refunds and civil penalties.
- The FTC’s Health Products Compliance Guidance sets the substantiation bar at competent and reliable scientific evidence, generally randomized controlled human clinical testing for health-related efficacy claims.
- FDA’s enforcement discretion period for certain HCT/P products ended May 31, 2021, and FDA states there are currently no FDA-approved exosome products.
- Autologous PRP prepared from a patient’s own blood sits in a different regulatory posture than cell and tissue products, but the marketing claims you make about it are governed by the same FTC standard.
On January 8, 2025, the Federal Trade Commission announced federal court orders permanently banning the co-founders of the Stem Cell Institute of America from advertising, marketing, promoting, offering for sale, or selling any regenerative medicine treatment, and requiring them to pay $5,155,146 in consumer refunds and civil penalties. According to the FTC, one founder was a chiropractor and the other a former chiropractor. The company they built in 2015 trained chiropractors and other practitioners to market stem cell therapy in their practices, supplied client clinics with a library of sample advertisements, and ran the same playbook in its own clinic, where injections were priced at up to $5,000 each. The court had granted summary judgment for the FTC and the State of Georgia on all counts in March 2024.
Read that case carefully, because the charge was not that the treatments harmed anyone and not that the practitioners lacked licenses. The charge was deceptive advertising: false and misleading claims about efficacy and approval, distributed to the public and to other clinics. This is the pattern in nearly every regenerative medicine enforcement action worth studying. The regulator that shows up first is usually the one policing what you said, not what you injected.
It is not an isolated case. In October 2018 the FTC settled charges against a clinic operator over claims that amniotic stem cell therapy could treat Parkinson’s disease, autism, macular degeneration, cerebral palsy, multiple sclerosis, and other serious conditions; the companies had taken in at least $3.31 million over roughly three years. If you are running or considering a regenerative program inside an integrated chiropractic practice, those two files are your compliance curriculum.
Two Regulators, Two Different Questions
FDA asks what the product is. Under the agency’s regulatory framework for regenerative medicine products, human cells, tissues, and cellular and tissue-based products are evaluated against criteria including minimal manipulation and homologous use. Products that meet the criteria in 21 CFR 1271.10(a) are regulated solely under Section 361 of the Public Health Service Act. Products that do not – because they are more than minimally manipulated, or because they are marketed for a non-homologous use – are regulated as drugs or biologics and require an approved biologics license application or an active investigational new drug application. FDA’s 2017 warning letter to US Stem Cell Clinic addressed adipose tissue processed into stromal vascular fraction, which the agency took the position did not qualify for the same surgical procedure exception because the tissue was not implanted in the same form after processing.
The enforcement discretion period FDA had extended for certain products ended on May 31, 2021. FDA’s consumer alert on regenerative medicine products states plainly that there are currently no FDA-approved exosome products, and warns that stem cell, exosome, adipose, umbilical cord blood, Wharton’s jelly, and amniotic fluid products have not been approved for orthopedic conditions including osteoarthritis, tendonitis, disc disease, or pain.
FTC asks a different question: what did you tell the patient? The FTC’s Health Products Compliance Guidance, issued in December 2022, defines the substantiation standard as competent and reliable scientific evidence – testing conducted and evaluated objectively by qualified experts, generally accepted in the field to yield accurate results, and sufficient in quality and quantity in light of the entire body of relevant evidence. For health-related efficacy claims, the guidance points to randomized, controlled human clinical testing as the general expectation. Testimonials, before-and-after anecdotes, and mechanism-of-action reasoning do not meet that bar.
The regulator that arrives first is usually not asking what you injected. It is asking what you promised.
Where the Claims Actually Live
Most practices audit their website and stop. The claims that create exposure are distributed across places nobody reviews: the seminar deck, the scripted consultation the care coordinator delivers, the printed comparison sheet handed out at the front desk, the paid social ads, the testimonial videos, the financing conversation, and the informed consent form itself. The Stem Cell Institute matter turned in part on marketing materials supplied to clinics and on free educational seminars used to recruit patients.
A practical audit list: every efficacy claim in writing or on video, with the specific evidence you would produce if asked; every use of the words cure, reverse, regenerate, or heal; any implication of FDA approval or clearance, including logos and phrases like FDA-registered facility that patients read as endorsement; every condition named in advertising against the conditions your evidence actually supports; and every claim your staff makes verbally that is not in any document. That last one is usually the biggest gap, and the only way to close it is to write the consultation script, train to it, and listen to it being delivered.
Program Economics Without the Claims
Here is the harder business question. If you remove every claim you cannot substantiate under the FTC standard, does the service line still work? For many practices the honest answer is that the economics were built on the claims. Patients paid four figures per injection because they were told it would regenerate cartilage or eliminate the need for surgery. Take that away and the conversion rate falls.
That is a real finding, not a reason to panic. A defensible regenerative program is generally smaller, priced against a realistic conversion rate, positioned within a broader conservative care pathway rather than as a standalone miracle, and consented with explicit language about regulatory status and evidence limitations. Autologous platelet-rich plasma prepared from a patient’s own blood occupies a different regulatory posture than cell and tissue products, and it is more commonly used, but the marketing claims you make about PRP are governed by exactly the same FTC substantiation standard. The device used to prepare it is separately regulated. None of that makes PRP a claims-free zone.
Also model the compliance carrying cost honestly: legal review of marketing, staff training time, consent documentation, product sourcing diligence on any supplier, and the malpractice coverage question, which is not automatic for these procedures. A program that pencils only when you assume zero compliance overhead is not a program, it is an unpriced liability.
From the Field
A two-location integrated practice in the Midwest had built a regenerative program that produced meaningful cash revenue and a growing unease. The owner had bought a turnkey marketing package from a vendor, and the seminar deck, the website, and the consultation script all made efficacy claims the owner could not have supported if asked. Our engagement started with a claims inventory across every asset, including a recording of the actual seminar as delivered, which contained claims that appeared in no written material. Working with the practice’s health care counsel, we rewrote the website and seminar content to the FTC substantiation standard, replaced the consultation script, and rebuilt the consent form to state regulatory status and evidence limitations explicitly. Then we rebuilt the economics: repriced the offering against a lower and more realistic conversion rate, folded it into a conservative care pathway rather than a standalone pitch, and retrained the two care coordinators over three weeks with live call review. Program revenue fell about 30 percent in the first quarter and recovered to roughly 85 percent of prior levels within three quarters, on materially lower risk and with a marketing file the owner can hand to counsel in an afternoon.
Advice, Execution, and Who Does the Work
Regulatory posture on cell and tissue products is federal, but scope of practice, supervision requirements, informed consent standards, and advertising rules for licensed practitioners are all state law and they vary. Anything high-stakes here – product sourcing, entity structure, whether a given procedure is within scope for the provider performing it, self-disclosure of past marketing – belongs with health care counsel licensed in your state before you act.
A consultant can perform the claims audit, deliver the rewritten language, and give you a compliance checklist. That is a legitimate and often more economical purchase, particularly if you have a marketing coordinator and an office manager who can execute against the list without further help. If that is your situation, buy the consulting engagement.
What we find is that the residual risk is not on the website. It is in what a care coordinator says on visit two when a patient asks whether this will let them avoid surgery. Changing that requires writing the script, training to it, listening to it delivered, correcting it, and listening again. A fractional executive does the audit and then does that work in your building. “Fractional executive” is an unregulated label and some firms sell ordinary consulting under it, so ask directly whether the person will be sitting in on consultations and retraining your staff, or delivering a document. Both are honest services. Only one changes what a patient hears.
Sources
- Federal Trade Commission, Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments (January 2025) — https://www.ftc.gov/news-events/news/press-releases/2025/01/stem-cell-institute-co-founders-companies-banned-marketing-stem-cell-treatments-ordered-pay-more-51
- Federal Trade Commission, FTC Stops Deceptive Health Claims by a Stem Cell Therapy Clinic (October 2018) — https://www.ftc.gov/news-events/news/press-releases/2018/10/ftc-stops-deceptive-health-claims-stem-cell-therapy-clinic
- Federal Trade Commission, Health Products Compliance Guidance (December 2022) — https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
- U.S. Food and Drug Administration, Framework for the Regulation of Regenerative Medicine Products — https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/framework-regulation-regenerative-medicine-products
- U.S. Food and Drug Administration, Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes — https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes
- U.S. Food and Drug Administration, Warning Letter: US Stem Cell Clinic, LLC (August 2017) — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-stem-cell-clinic-llc-524470-08242017
More in the Integrated Chiropractic Series
- How a DC Legally Integrates an MD or NP: The MSO Structure Explained — the legal architecture that makes a DC-owned medical practice work, and the places it quietly fails.
- Adding a Medical Provider: The Break-Even Math Nobody Runs First — the break-even, compensation, and ramp model to build before you sign a medical provider.
- Credentialing and Billing the Medical Side: Where Integrated Practices Get Burned — enrollment timelines, incident-to, split or shared visits, and the documentation that has to exist behind each.
- Staffing a Multidisciplinary Clinic Without Building Two Clinics in One Building — the roles, schedule template, and internal referral workflow that keep an integrated clinic from splitting in two.
See the full Integrated Chiropractic practice management page →